Hubbry Logo
Para-MethoxyamphetaminePara-MethoxyamphetamineMain
Open search
Para-Methoxyamphetamine
Community hub
Para-Methoxyamphetamine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Para-Methoxyamphetamine
Para-Methoxyamphetamine
Para-Methoxyamphetamine
View on Wikipedia
from Wikipedia

para-Methoxyamphetamine
Clinical data
Other namespara-Methoxyamphetamine; p-Methoxyamphetamine; PMA; 4-Methoxyamphetamine; 4-MA; 4-MeO-A
Routes of
administration		Oral
Drug classSelective serotonin releasing agent (SSRA); Serotonergic psychedelic
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1-(4-methoxyphenyl)propan-2-amine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.525 Edit this at Wikidata
Chemical and physical data
FormulaC10H15NO
Molar mass165.236 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1CC(C)N)OC
  • InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3 checkY
  • Key:NEGYEDYHPHMHGK-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

para-Methoxyamphetamine (PMA), also known as 4-methoxyamphetamine (4-MA), is a designer drug of the amphetamine class with serotonergic effects.[2][3][4] Unlike other similar drugs of this family, PMA does not produce stimulant, euphoriant, or entactogenic effects,[5] and behaves more like an antidepressant in comparison,[6] though it does have some psychedelic properties.[7][8]

PMA has been found in tablets touted as MDMA (ecstasy)[9][10][11][12] although its effects are markedly different compared to those of MDMA. The consequences of such deception have often included hospitalization and death for unwitting users. PMA is commonly synthesized from anethole, the flavor compound of anise and fennel, mainly because the starting material for MDMA, safrole, has become less available due to law enforcement action, causing illicit drug manufacturers to use anethole as an alternative.[13]

Effects

[edit]

According to Alexander Shulgin in PiHKAL (Phenethylamines I Have Known and Loved), the effects of PMA at doses of 50 to 80 mg orally included hypertension, diethyltryptamine (DET)-reminiscent effects, distinct after-images, and some paresthesia, "intoxication" or alcohol-like intoxication, and no psychedelic effects.[3][14] In clinical studies, PMA produced "excitation, other central effects, and sympathomimetic effects, but similarly no psychotomimetic effects.[14] Animal studies suggested that PMA would have partial psychedelic effects, but this did not seem to prove true in humans.[14] PMA only partially substituted for the psychostimulant amphetamine in drug discrimination tests.[14][15][16] It did not substitute for MDMA in rodents, suggesting lack of entactogenic effects.[15]

Adverse effects

[edit]

PMA has been associated with numerous adverse reactions including death.[17][18] Effects of PMA ingestion include many effects of the hallucinogenic amphetamines including accelerated and irregular heartbeat, blurred vision, and a strong feeling of intoxication that is often unpleasant. At high doses unpleasant effects such as nausea and vomiting, severe hyperthermia and hallucinations may occur. The effects of PMA also seem to be much more unpredictable and variable between individuals than those of MDMA, and sensitive individuals may die from a dose of PMA by which a less susceptible person might only be mildly affected.[19] While PMA alone may cause significant toxicity, the combination of PMA with MDMA has a synergistic effect that seems to be particularly hazardous.[20] Since PMA has a slow onset of effects, several deaths have occurred where individuals have taken a pill containing PMA, followed by a pill containing MDMA some time afterwards due to thinking that the first pill was not active.[21]

Overdose

[edit]

PMA overdose can be a serious medical emergency that may occur at only slightly above the usual recreational dose range, especially if PMA is mixed with other stimulant drugs such as cocaine or MDMA. Characteristic symptoms are pronounced hyperthermia, tachycardia, and hypertension, along with agitation, confusion, and convulsions. PMA overdose also tends to cause hypoglycaemia and hyperkalaemia, which can help to distinguish it from MDMA overdose. Complications can sometimes include more serious symptoms such as rhabdomyolysis and cerebral hemorrhage, requiring emergency surgery. There is no specific antidote, so treatment is symptomatic, and usually includes both external cooling, and internal cooling via IV infusion of cooled saline. Benzodiazepines are used initially to control convulsions, with stronger anticonvulsants such as phenytoin or thiopental used if convulsions continue. Blood pressure can be lowered either with a combination of alpha blockers and beta blockers (or a mixed alpha/beta blocker), or with other drugs such as nifedipine or nitroprusside. Serotonin antagonists and dantrolene may be used as required. Despite the seriousness of the condition, the majority of patients survive if treatment is given in time, however, patients with a core body temperature over 40 °C at presentation tend to have a poor prognosis.[22]

Pharmacology

[edit]

Pharmacodynamics

[edit]
Monoamine release of PMATooltip para-methoxyamphetamine and related agents (EC50Tooltip Half maximal effective concentration, nM)
Compound 5-HTTooltip Serotonin NETooltip Norepinephrine DATooltip Dopamine Ref
d-Amphetamine 698–1,765 6.6–7.2 5.8–24.8 [23][24]
d-Methamphetamine 736–1,292 12.3–13.8 8.5–24.5 [23][25]
2-Methoxyamphetamine ND 473 1,478 [26]
3-Methoxyamphetamine ND 58.0 103 [26]
para-Methoxyamphetamine (PMA) ND 166 867 [26][27]
PMMATooltip para-Methoxymethamphetamine ND ND ND ND
  (S)-PMMA 41 147 1,000 [15][28][27]
  (R)-PMMA 134 >14,000 1,600 [15][28][27]
4-Methylamphetamine (4-MA) 53.4 22.2 44.1 [29][30][26]
4-Methylmethamphetamine (4-MMA) 67.4 66.9 41.3 [31][32]
para-Chloroamphetamine (PCA) 28.3 23.5–26.2 42.2–68.5 [30][26][33][34]
para-Chloromethamphetamine (PCMA) 29.9 36.5 54.7 [33][34]
Methedrone (4-MeO-MC) 120–195 111 506–881 [35][36][37][38][39]
Mephedrone (4-MMC) 118.3–122 58–62.7 49.1–51 [25][24][36][38][39]
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. The assays were done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs: [40][41]

PMA acts as a selective serotonin releasing agent (SSRA) with weak effects on dopamine and norepinephrine transporters.[42][43][44][45] Its EC50Tooltip half-maximal effective concentration values for induction of monoamine release are 166 nM for dopamine and 867 nM for norepinephrine in rat brain synaptosomes, whereas serotonin was not reported.[26][27] The drug has been found to robustly increase brain serotonin levels and to weakly increase brain dopamine levels in rodents in vivo.[46] Relative to MDMA, PMA appears to be considerably less effective as a releaser of serotonin, with properties more akin to a serotonin reuptake inhibitor in comparison.[47]

PMA has also been shown to act as a potent monoamine oxidase inhibitor (MAOI), specifically as a reversible inhibitor of the enzyme monoamine oxidase A (MAO-A) with no significant effects on monoamine oxidase B (MAO-B).[48][49] The IC50Tooltip half-maximal inhibitory concentration of PMA for MAO-A inhibition has been reported to be 300 to 600 nM.[50]

PMA shows very low affinities for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors.[45] Its affinities (Ki) for these receptors have been reported to be >20,000 nM, 11,200 nM, and >13,000 nM, respectively.[45] In another earlier study, PMA similarly showed very weak affinity for serotonin receptors, including the serotonin 5-HT1 and 5-HT2 receptors (Ki = 79,400 nM and 33,600 nM, respectively).[51][52] On the other hand, PMA shows much higher affinities for the mouse and rat trace amine-associated receptor 1 (TAAR1).[45]

PMA evokes robust hyperthermia in rodents while producing only modest hyperactivity and serotonergic neurotoxicity, substantially lower than that caused by MDMA, and only at very high doses.[43][44][47] Accordingly, it is not self-administered by rodents unlike amphetamine and MDMA.[5] Anecdotal reports by humans suggest it is not particularly euphoric at all, perhaps even dysphoric in contrast.[citation needed]

It appears that PMA elevates body temperatures dramatically; the cause of this property is suspected to be related to its ability to inhibit MAO-A and at the same time releasing large amounts of serotonin, effectively causing serotonin syndrome.[47][49] Amphetamines, especially serotonergic analogues such as MDMA, are strongly contraindicated to take with MAOIs. Many amphetamines and adrenergic compounds raise body temperatures, whereas some tend to produce more euphoric activity or peripheral vasoconstriction, and may tend to favor one effect over another. It appears that PMA activates the hypothalamus much more strongly than MDMA and other drugs like ephedrine, thereby causing rapid increases in body temperature (which is the major cause of death in PMA mortalities).[53][54][55] Many people taking PMA try to get rid of the heat by taking off their clothes, taking cold showers or wrapping themselves in wet towels, and even sometimes by shaving off their hair.[56]

History

[edit]

PMA first came into circulation in the early 1970s, where it was used intentionally as a substitute for the hallucinogenic properties of LSD.[3] It went by the street names of "Chicken Powder" and "Chicken Yellow" and was found to be the cause of a number of drug overdose deaths (the dosages taken being in the range of hundreds of milligrams) in the United States and Canada from that time.[57] Between 1974 and the mid-1990s, there appear to have been no known fatalities from PMA.[58]

Several deaths reported as MDMA-induced in Australia in the mid-1990s are now considered to have been caused by PMA, the users unaware that they were ingesting PMA and not MDMA as they had intended.[12] There have been a number of PMA-induced deaths around the world since then.[59][60]

In July 2013, seven deaths in Scotland were linked to tablets containing PMA that had been mis-sold as ecstasy and which had the Rolex crown logo on them.[10] Several deaths in Northern Ireland, Particularly East Belfast were also linked to "Green Rolex" pills during that month.[61]

In 2014, 2015 and early 2016, PMA sold as ecstasy was the cause of more deaths in the United States, United Kingdom, Netherlands, and Argentina. The pills containing the drug were reported to be red triangular tablets with a "Superman" logo.[11][62][63][64]

The Red Ferarri pills are a new press of the Superman logo tablets that were reported to be found in Germany and Norway from 2016 to 2017.[65]

Society and culture

[edit]
[edit]

International

[edit]

PMA is a Schedule I drug under the Convention on Psychotropic Substances.[66]

Australia

[edit]

PMA is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015).[67] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[67]

Finland

[edit]

Substance is scheduled in decree of the government on amending the government decree on substances, preparations and plants considered to be narcotic drugs.[68][69]

Germany

[edit]

PMA is part of the Appendix 1 of the Betäubungsmittelgesetz. Therefore, owning and distribution of PMA is illegal.

Netherlands

[edit]

On 13 June 2012 Edith Schippers, Dutch Minister of Health, Welfare and Sport, revoked the legality of PMA in the Netherlands after five deaths were reported in that year.[70]

United Kingdom

[edit]

PMA is a Class A drug in the UK.[71]

United States

[edit]

PMA is classified as a Schedule I hallucinogen under the Controlled Substances Act in the United States.[72]

Economics

[edit]

Distribution

[edit]

Because PMA is given out through the same venues and distribution channels that MDMA tablets are, the risk of being severely injured, hospitalized or even dying from use of ecstasy increases significantly when a batch of ecstasy pills containing PMA starts to be sold in a particular area.[73] PMA pills could be a variety of colours or imprints, and there is no way of knowing just from the appearance of a pill what drug(s) it might contain.[74][75] Notable batches of pills containing PMA have included Louis Vuitton,[76] Mitsubishi Turbo, Blue Transformers, Red/Blue Mitsubishi and Yellow Euro pills. Also PMA has been found in powder form.[77]

Analogues

[edit]

Four analogues of PMA have been reported to be sold on the black market, including PMMA, PMEA,[78] 4-ETA and 4-MTA. These are the N-methyl, N-ethyl, 4-ethoxy and 4-methylthio analogues of PMA, respectively. PMMA and PMEA are anecdotally weaker, more "ecstasy-like" and somewhat less dangerous than PMA itself, but can still produce nausea and hyperthermia similar to that produced by PMA, albeit at slightly higher doses. 4-EtOA was briefly sold in Canada in the 1970s, but little is known about it.[3] 4-MTA, however, is even more dangerous than PMA and produces strong serotonergic effects and intense hyperthermia, but with little to no euphoria, and was implicated in several deaths in the late 1990s.

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Para-Methoxyamphetamine

View on Grokipedia
from Grokipedia
Para-methoxyamphetamine (PMA), also known as 4-methoxyamphetamine, is a synthetic and derivative that acts primarily as a potent and selective serotonin releasing agent, producing hallucinogenic, stimulant, and entactogenic effects. With the chemical formula C10H15NO, PMA exhibits structural similarity to methylenedioxyamphetamine (MDA) but is distinguished by its methoxy group at the para position on the phenyl ring. It is classified as a Schedule I controlled substance under the United States , reflecting its lack of accepted medical use and high abuse potential. PMA has gained notoriety in recreational drug contexts for being frequently adulterated into or misrepresented as 3,4-methylenedioxymethamphetamine (, commonly known as ecstasy), due to superficial similarities in appearance and initial subjective effects, though PMA's onset is markedly delayed. This substitution has led to clusters of overdose deaths worldwide, as PMA demonstrates greater toxicity than , inducing severe , , , seizures, and cardiovascular failure at doses that users might tolerate if anticipating . Empirical data from forensic analyses indicate PMA's lethality stems from its enhanced serotonergic release coupled with weaker and norepinephrine activity, exacerbating thermoregulatory disruption and in users. Despite its psychoactive profile, PMA lacks therapeutic applications and is primarily encountered in illicit markets, where its synthesis from precursors like underscores risks in clandestine production.

Chemistry

Molecular Structure and Properties

Para-methoxyamphetamine (PMA), chemically known as 4-methoxyamphetamine, possesses the molecular formula C10H15NO and a of 165.23 g/mol. Its IUPAC name is 1-(4-methoxyphenyl)propan-2-amine, with the CAS number 64-13-1. The molecular structure consists of a benzene ring substituted at the 1-position with a β-methylaminoethyl chain (-CH2-CH(CH3)-NH2) and at the 4-position (para) with a (-OCH3). This configuration renders PMA a , introducing lipophilic and electronic modifications compared to unsubstituted via the para-methoxy substituent. PMA is chiral due to the in the , existing as (R)- and (S)-enantiomers, though it is typically synthesized and encountered as the . Physical properties of PMA include a computed boiling point of approximately 258 °C at standard pressure and a of 107.5 °C, indicative of its volatility and flammability risks. The free base form exhibits limited solubility in but good solubility in organic solvents, facilitating extraction and purification processes. Specific melting and boiling points for the base are not consistently reported in available chemical databases, likely due to its status as a limiting routine characterization. The pKa of the group is approximately 10.0, reflecting its basic character similar to other amphetamines.

Synthesis and Precursors

Para-methoxyamphetamine (PMA) is primarily synthesized through methods analogous to those used for other substituted amphetamines, with the being a predominant route in clandestine laboratories. In this process, 1-(4-methoxyphenyl)propan-2-one (also known as 4-methoxyphenylacetone) reacts with or under heating, forming N-formyl derivatives that are subsequently hydrolyzed under acidic conditions to yield PMA. This method generates characteristic impurities, including 4-methyl-5-(4-methoxyphenyl)pyrimidine and other arylpyrimidines, which serve as route-specific markers detectable via gas chromatography-mass spectrometry (GC-MS) for forensic attribution. The key intermediate precursor, 1-(4-methoxyphenyl)propan-2-one, is often derived from , a primary constituent of oil (derived from star anise or ). undergoes oxidation or to form the , which then proceeds to amination; its low cost, commercial availability as a agent, and lack of stringent controls facilitate large-scale illicit production. Forensic analyses of seized PMA batches have confirmed anethole-derived pathways through impurity profiling, including residual alkenes and oxidation byproducts identifiable by GC-MS and headspace . Anise oil seizures exceeding hundreds of kilograms have been directly linked to PMA manufacturing operations. Alternative precursors include para-methoxybenzaldehyde, which can be homologated to the propanone intermediate via nitroaldol condensation followed by reduction, though this is less common in illicit contexts due to higher complexity. Reductive amination of the ketone using and a like represents a potential non-Leuckart route, but forensic indicates Leuckart dominance for PMA, yielding distinct impurity profiles absent in reductive methods. Regulatory schedules under the DEA list PMA as a Schedule I substance, with upstream precursors like unregulated, contributing to its persistence in recreational markets despite controls on the final product.

Pharmacology

Pharmacodynamics

Para-methoxyamphetamine (PMA), also known as 4-methoxyamphetamine, functions primarily as a potent and selective serotonin releasing agent within the class. It interacts with the (SERT) to inhibit and induce efflux of serotonin into the synaptic cleft, thereby elevating extracellular serotonin concentrations and enhancing serotonergic . This transporter-mediated release mechanism is evidenced by the blockade of PMA-induced serotonin efflux upon pretreatment with serotonin uptake inhibitors such as chlorimipramine or . In comparison to other amphetamines, PMA exhibits greater selectivity for SERT over the (DAT) and (NET), resulting in relatively weak dopamine release and uptake inhibition alongside minimal noradrenergic effects. Neurochemical studies in rat brain slices demonstrate that PMA potently blocks serotonin uptake while showing negligible impact on uptake or release, contrasting with the more balanced monoamine profile of compounds like . This serotonergic dominance contributes to PMA's limited euphoriant or properties and heightened propensity for serotonin syndrome-like effects, including and cardiovascular strain. PMA additionally inhibits and B (MAO-A/B), as well as the synaptic vesicular amine transporter (VMAT2), which disrupts intraneuronal storage and degradation of monoamines, further amplifying synaptic serotonin availability. It acts as an at alpha-1A, alpha-1D, and alpha-2A adrenergic receptors, potentially mediating , , and other autonomic responses observed in users. Repeated exposure to PMA has been shown to downregulate SERT binding sites in cortical regions without proportionally depleting serotonin content, suggesting adaptive neurochemical changes akin to those seen with chronic serotonergic stimulants.

Pharmacokinetics

Para-methoxyamphetamine (PMA) is rapidly absorbed following oral administration, with onset of effects typically occurring within 20-60 minutes, consistent with its structural similarity to other amphetamines that exhibit high gastrointestinal bioavailability. Limited human pharmacokinetic data exist due to its illicit status, but animal studies indicate efficient distribution to tissues, including pronounced penetration of the blood-brain barrier, as observed for PMA itself and related metabolites in rat models. The primary metabolic pathway involves hepatic O-demethylation to (p-hydroxyamphetamine), mediated by enzymes, with minor pathways yielding N-hydroxy-p-methoxyamphetamine, p-methoxyphenylacetone, and , as identified using liver preparations from rabbits, guinea pigs, and rats. Interspecies variation is notable; in guinea pigs, O-demethylation predominates, while rats show greater production of N-hydroxylated metabolites. Human metabolism likely follows similar demethylation, though polymorphisms may influence rates, analogous to other amphetamines. Excretion occurs mainly via the kidneys, with appearing in urine primarily as conjugates (e.g., glucuronides or sulfates, comprising up to 73% of the dose in guinea pigs) and a smaller fraction free (approximately 4%). Unchanged PMA constitutes a minor urinary component, reflecting extensive biotransformation. No precise elimination has been established in humans, but postmortem tissue distributions in overdose cases suggest relatively slow clearance compared to shorter-acting amphetamines, contributing to prolonged effects and risk.

Effects on Humans

Desired Effects

Users seek para-methoxyamphetamine (PMA) primarily under the false assumption that it is 3,4-methylenedioxymethamphetamine (), anticipating effects such as , emotional openness, sensory enhancement, and energetic sociability associated with ecstasy. In intentional or low-dose recreational contexts, reported positive effects include amphetamine-like manifesting as heightened , focus, and talkativeness, with some users experiencing mild mood elevation and clarity sufficient for enhanced performance in social or cognitive tasks. At doses around 2-3 mg/kg, PMA can produce stimulation without pronounced hallucinogenic qualities, potentially contributing to perceived benefits like increased energy for prolonged activity, though these are weaker and less consistent than those of or traditional amphetamines. User accounts occasionally note a subtle serotonergic component yielding brief euphoria or perceptual sharpening, akin to low-dose stimulants like , but such reports are rare and often confounded by polydrug use or initial misidentification. The slow onset of effects, typically 1-2 hours after oral ingestion, frequently prompts redosing in pursuit of desired , exacerbating risks rather than enhancing positives; intentional users report these effects as less rewarding than expected, with dominating over any empathogenic warmth. Overall, PMA lacks robust entactogenic appeal, and its recreational value derives more from pharmacological overlap with sympathomimetics—elevating heart rate and arousal—than from unique desirable qualities.

Adverse Effects

Para-methoxyamphetamine (PMA) produces a range of sympathomimetic and serotonergic adverse effects, including , , agitation, , seizures, and . These symptoms often arise due to PMA's potent serotonin release and inhibition, exacerbating excitation and autonomic instability. Unlike , PMA's delayed onset may prompt users to redose, intensifying . Thermoregulatory disruption is prominent, with PMA inducing severe through serotonergic mechanisms, leading to , , and in clinical cases. secondary to muscle breakdown appears more specific to PMA intoxication compared to other amphetamines. Cardiovascular complications include arrhythmias and myocardial strain from elevated and . Neurological effects encompass serotonin syndrome-like features such as confusion, tremors, and convulsions, progressing to hemorrhage in severe instances. Animal studies confirm PMA's neurochemical profile contributes to these outcomes, with robust hyperthermia and modest hyperactivity observed in rodents. Human case reports document renal failure and hepatic dysfunction as downstream consequences. Overall, PMA's toxicity profile exceeds that of MDMA, with fatalities linked to cumulative organ failure rather than direct overdose thresholds.

Overdose and Lethality

Para-methoxyamphetamine (PMA) overdose manifests primarily through serotonin syndrome-like symptoms, including severe (often exceeding 40°C), , , agitation, seizures, , and , which can rapidly progress to multi-organ failure and death. These effects stem from PMA's potent serotonergic and sympathomimetic actions, which disrupt and cardiovascular more aggressively than structurally similar amphetamines like . In animal models, PMA exhibits high , with 6-hour LD50 values in mice indicating greater potency than or MDA, though 24-hour LD50s show comparable lethality across these compounds. Human lethality is well-documented in case reports, with fatalities occurring at relatively low doses due to PMA's delayed onset of effects (often 2-4 hours), prompting users to redose under the misconception of impure or ineffective ecstasy tablets. Postmortem femoral blood concentrations in fatal PMA overdoses have ranged from 0.2 to 2.5 mg/L, with many cases involving co-ingestion of alcohol or other stimulants exacerbating . For instance, three Australian cases from the early 2000s involved young adults who ingested PMA-adulterated pills, resulting in hyperthermic deaths despite medical intervention; blood levels were 0.64 mg/L, 1.1 mg/L, and 2.5 mg/L, respectively. Similarly, Danish reports describe fatalities from PMA/PMMA combinations, where even sub-milligram-per-liter concentrations contributed to death via and organ failure four days post-ingestion in one instance. PMA's narrow therapeutic-to-toxic ratio—estimated from data at around 50-60 mg/kg for —renders it far more hazardous than , with synergistic risks when combined, as seen in a Belgian case where co-use amplified cardiovascular collapse. Survival from overdose is rare without aggressive cooling, , and supportive care, but even then, long-term sequelae like renal failure persist in non-fatal exposures. data from outbreaks, such as those in and , link PMA to clusters of deaths among recreational users, underscoring its role as a "death pill" substitute in illicit markets.

History

Discovery and Early Research

Para-methoxyamphetamine (PMA), chemically 1-(4-methoxyphenyl)propan-2-amine, was synthesized through standard derivatization routes, such as the of 4-methoxyphenylacetone or the on the corresponding precursor, though precise initial synthetic protocols from primary sources remain sparsely documented prior to recreational emergence. Early pharmacological investigations emerged in the late amid broader research into substituted amphetamines for psychoactive potential, focusing on behavioral and effects rather than therapeutic applications. A key 1970 study examined PMA's impact on grouped and aggressive rats, finding it produced profound behavioral disruption at low doses (3 mg/kg subcutaneously), yielding a hallucinogenic profile akin to (25 mg/kg) but distinct from pure stimulants like , with effects including stereotyped hyperactivity and . This positioned PMA as a serotonergically mediated among analogs, contrasting with dopamine-dominant congeners. Subsequent early human research in 1971 analyzed urinary excretion after (20-30 mg doses), revealing rapid with 30-40% recovery as unchanged drug and metabolites within 24 hours, alongside detectable plasma levels peaking at 1-2 hours post-ingestion; the study noted mild effects but emphasized its potential for serotonin release over catecholamine pathways. These findings underscored PMA's unique profile—potentially reversible monoamine oxidase inhibition and serotonin-specific actions—but lacked extensive safety data, predating widespread toxicity recognition. Limited animal neuropharmacology from the era confirmed dose-dependent serotonin depletion in brain tissue, informing its classification as a designer with risks exceeding typical amphetamines.

Emergence in Recreational Markets

Para-methoxyamphetamine (PMA) first entered illicit recreational markets in the early 1970s, primarily in , where it circulated as a novel synthetic derivative marketed for its and purported hallucinogenic effects. Initially encountered as a street drug amid the era's experimentation with analogs and psychedelics, PMA was distributed in tablet or powder form, often without clear labeling of its composition or potency. Its appearance coincided with growing demand for accessible psychoactive substances, but limited pharmacological knowledge at the time contributed to unpredictable dosing and adverse outcomes. In , PMA's recreational debut was documented in , where it emerged as a new street drug by early 1973. Between March and August 1973, nine fatalities among young users were directly attributed to PMA ingestion, representing some of the earliest confirmed deaths from its recreational consumption. These cases involved oral intake of the substance, typically in social or party settings, and were characterized by , seizures, and cardiovascular collapse, prompting medical alerts and highlighting PMA's relative to more established drugs like or MDA. The rapid clustering of deaths led to PMA acquiring the street moniker "death" and a temporary retreat from markets. Concurrent reports from the noted PMA's presence by 1970, with initial fatalities in 1972 linked to batches mis-sold as methylenedioxyamphetamine (MDA), a related . This pattern of substitution—exploiting similarities in and desired —facilitated its entry into recreational circuits but amplified risks due to PMA's narrower therapeutic window and greater serotonergic overload. By the mid-1970s, heightened awareness of its lethality, disseminated through reports, curtailed widespread availability, though sporadic reintroductions occurred later as an in ecstasy mimics.

Notable Outbreaks and Fatalities

In the mid-1990s, para-methoxyamphetamine (PMA) reemerged in , particularly in , where it was frequently substituted for 3,4-methylenedioxymethamphetamine (, commonly known as ecstasy), leading to a cluster of fatalities. By 1998, PMA accounted for a marked increase in amphetamine derivative deaths in the region, comprising the majority of acute ecstasy-attributed fatalities since 1994 due to its higher toxicity and delayed onset, which prompted users to redose. Between 1995 and 2001, PMA was linked to at least 11 deaths across . A similar outbreak occurred in in 2001, involving six PMA-related fatalities misattributed initially to use. In 2011, experienced a major incident combining PMA and para-methoxymethamphetamine (PMMA), resulting in 24 deaths; post-mortem analyses revealed elevated whole blood concentrations of these compounds (PMA: mean 1.7 mg/L, range 0.3–4.2 mg/L; PMMA: mean 2.1 mg/L, range 0.5–5.6 mg/L), confirming acute intoxication as the primary cause amid widespread adulteration of ecstasy tablets. In 2014, reported six fatalities from PMA/PMMA sold as ecstasy, prompting public health warnings about its hallucinogenic properties and greater lethality compared to . Scattered PMA deaths have also been documented in (six cases with femoral blood levels of 0.24–4.9 mg/L) and the (multiple incidents in the late and early ), often involving misrepresentation and contributing to PMA's reputation as a "death" drug. These outbreaks highlight PMA's pattern of causing , seizures, and cardiovascular collapse when ingested under the assumption of 's effects.

Societal and Cultural Context

Illicit Use and Misrepresentation

Para-methoxyamphetamine (PMA) is consumed illicitly primarily in oral tablet or capsule form at recreational settings such as parties and raves, where it is sought for its stimulant and mild hallucinogenic effects resembling those of 3,4-methylenedioxymethamphetamine (MDMA). Users typically ingest doses ranging from 20 to 100 mg, though accurate dosing is challenging due to inconsistent purity in street products. Its onset of action is delayed, often requiring 1-2 hours, which can lead to repeated dosing in pursuit of immediate euphoria. PMA is frequently misrepresented as or pure ecstasy in the illicit market, exploiting visual similarities in pressed pills and superficial overlap in serotonergic effects, despite PMA's greater toxicity and narrower therapeutic window. This substitution has been documented since at least late 1994 in , where PMA emerged in ecstasy mimics, prompting fatalities among users unaware of the adulteration. In the , a 2013 surge in PMA-laced pills sold as contributed to multiple overdose deaths, with confirming PMA as the primary agent rather than intended substances. Such misrepresentation persists due to clandestine production prioritizing cost over safety, with PMA's slower absorption profile exacerbating risks when users stack doses expecting 's quicker profile. The drug's nickname "Dr. Death" reflects its reputation in underground communities for unpredictable lethality when passed off as safer alternatives, underscoring how illicit misrepresentation amplifies hazards beyond intentional use. analyses emphasize reagent testing kits to distinguish PMA from , as visual and subjective cues alone fail to prevent exposure.

Public Health and Harm Reduction Debates

Public health concerns surrounding para-methoxyamphetamine (PMA) center on its elevated toxicity compared to , with which it is frequently confused in illicit markets, leading to clusters of overdoses characterized by , , and multiorgan failure. In documented outbreaks, such as those in Alberta, Canada, PMA exposure resulted in rapid cardiovascular collapse and higher fatality rates than typical incidents, often exacerbated by delayed onset prompting redosing. Empirical data from reports indicate PMA's narrower therapeutic window, with lethal doses as low as 100-200 mg in some cases, contrasting 's relative margin for error. Harm reduction strategies emphasize pre-use testing and cautious dosing to mitigate risks when PMA contamination is suspected in ecstasy products. Organizations recommend starting with low doses (e.g., 20-50 mg equivalents) and waiting at least two hours before redosing, alongside environmental controls like avoiding overheating and excessive hydration to prevent or exacerbation of . Reagent-based and spectroscopic pill-testing services at events have detected PMA, enabling user avoidance; studies from live music settings show such interventions correlate with reduced PMA-related presentations to medical services. agencies, including Australia's Alcohol and Drug Foundation, advocate availability for co-ingested opioids and education on PMA's distinct metabolic profile, which includes and not as prominent in . Debates persist over the efficacy and reach of these measures, particularly given PMA's status as an undesired rather than a primary recreational target, which complicates targeted interventions. Proponents of expanded argue it empowers informed decision-making without endorsing use, citing post-testing harm reductions in jurisdictions like following 2013 outbreaks. Critics, including some policy analysts, contend that user non-compliance—evident in online forums where harm warnings are reframed as exaggerated or pleasure-denying—undermines outcomes, with qualitative analyses revealing "counterpublic health" discourses that normalize PMA despite known lethality, as seen after the 2007 Annabel Catt fatality in the UK. Empirical evaluations question blanket prohibition's role, noting it drives underground adulteration, while evidence-based alternatives like regulated testing face resistance from zero-tolerance advocates prioritizing deterrence over pragmatic risk minimization. Overall, causal analyses link PMA harms primarily to supply-side impurities rather than demand, underscoring debates on supply-chain monitoring versus individual-level education.

Production and Distribution Patterns

Para-methoxyamphetamine (PMA) is synthesized illicitly through methods similar to those used for other amphetamines, with the being a prevalent route involving the of 4-methoxyphenylacetone followed by hydrolysis, often yielding detectable impurities such as N-formyl-4-methoxyamphetamine and N-acetyl-4-methoxyamphetamine identifiable via gas chromatography-mass spectrometry. Alternative pathways from the same precursor using have also been documented in clandestine contexts, though these produce distinct impurity profiles like secondary amines. Anethole, obtained from oil or , is frequently employed as a starting material due to its availability and the regulatory restrictions on (a key precursor for synthesis), involving to p-methoxyphenylacetone prior to ; this route has been confirmed through forensic analysis of seized samples and byproduct identification via headspace . Clandestine production remains small-scale, lacking the industrial mega-labs associated with , as evidenced by the absence of large PMA-specific laboratory seizures in global reports, with synthesis impurities serving as route-specific markers for profiling. Distribution patterns for PMA are characterized by its substitution or adulteration into tablets marketed as ecstasy (), exploiting consumer demand in and settings where visual similarity and delayed onset mimic expected effects, leading to episodic clusters of overdoses rather than steady supply chains. data indicate sporadic rather than sustained trafficking, with early peaks in the mid-1990s followed by declines—such as reductions to four incidents by in monitored jurisdictions—attributable to heightened awareness and testing, though resurgence occurs via opportunistic mixing in polysubstance pills. PMA enters markets primarily through European-sourced ecstasy networks or local ad hoc synthesis, with no evidence of dedicated large-volume export routes, as confirmed by UNODC aggregates categorizing it under minor amphetamine-type detections.

United States

Para-Methoxyamphetamine (PMA), also known as 4-methoxyamphetamine, is classified as a Schedule I under the federal (CSA), codified in 21 U.S.C. § 812. This classification was established through a temporary scheduling action on July 2, 1973, which became effective on September 21, 1973, following publication in the (38 FR 26447). Schedule I status under the CSA designates PMA as having a high potential for , no currently accepted use in treatment in the United States, and a lack of accepted safety for use under supervision. Consequently, the manufacture, distribution, dispensing, importation, exportation, or possession of PMA is prohibited for any purpose other than limited authorized research conducted under DEA registration and oversight. Violations are subject to criminal penalties, including fines and , with severity depending on quantity, intent, and prior offenses as outlined in 21 U.S.C. §§ 841–846. PMA does not qualify for exceptions under the (21 U.S.C. § 813), as it is explicitly enumerated in Schedule I rather than treated as a of another . State laws generally align with federal scheduling, prohibiting PMA under their controlled substances acts, though some jurisdictions impose additional reporting or precursor chemical restrictions. The DEA maintains PMA in Schedule I without provisions for medical or industrial use, reflecting assessments of its pharmacological risks, including serotonergic effects akin to amphetamines but with elevated toxicity.

International Controls

Para-methoxyamphetamine (PMA), chemically known as p-methoxy-α-methylphenylethylamine, is listed in Schedule I of the United Nations Convention on Psychotropic Substances (1971), subjecting it to the strictest international controls among psychotropic substances. The Commission on Narcotic Drugs (CND), acting on recommendations from the World Health Organization, formally included PMA in this schedule during its ninth special session on 13 February 1986, citing its high potential for abuse and lack of accepted medical value. Schedule I status requires signatory states—over 180 countries as of 2025—to prohibit production, manufacture, export, import, distribution, trade, possession, and use, with narrow exceptions only for scientific research or limited medical or diagnostic purposes under stringent licensing and record-keeping. These controls stem from Article 2 of the 1971 Convention, which mandates parties to apply measures ensuring effective control while preventing illicit trafficking, including penal provisions for violations comparable to those for narcotics. Unlike Schedules II–IV, which permit limited medical and scientific uses with quotas and authorizations, Schedule I substances like PMA face no provisions for therapeutic application, reflecting assessments of severe public health risks and dependence liability. The International Narcotics Control Board (INCB) oversees compliance, reporting annual statistics on seizures and enforcement, though PMA-specific global data remains sparse due to its relative rarity compared to other amphetamines. No subsequent amendments or rescheduling proposals for PMA have been adopted by the CND as of 2025, maintaining its prohibited status under the framework, which harmonizes national laws to curb cross-border movement. Related analogs, such as para-methoxymethylamphetamine (PMMA), were added to Schedule I in 2015, underscoring ongoing vigilance against methoxylated amphetamines but without altering PMA's classification. Parties to the Convention must also furnish annual reports to the UN Secretary-General on implementation, facilitating international cooperation via and mutual legal assistance under the treaty's provisions.

Country-Specific Bans

In , para-methoxyamphetamine (PMA) is classified as a dangerous drug under state-level legislation, such as Queensland's Drugs Misuse Regulation 1987, where it appears in Schedule 3 with a prescribed possession of 2.0 g, subjecting it to strict prohibitions on manufacture, possession, and supply. Nationally, PMA falls under Schedule 9 of the Poisons Standard, designating it a prohibited substance with no accepted therapeutic use, reinforced by historical associations with fatalities in the 1990s, particularly in . In the , PMA is controlled as a Class A substance under the , the highest tier of restriction that criminalizes its production, supply, possession, and importation with severe penalties, akin to those for or ; this status addresses its emergence in ecstasy adulteration, as noted in official drug monitoring reports. has regulated PMA since the 1970s following early overdose deaths, classifying it under Schedule I of the as a prohibited with no medical exemptions, prohibiting all non-authorized activities amid reports of its sporadic appearance in illicit markets. In , PMA (as 4-methoxyamphetamine) was explicitly listed in Schedule 1 of the until its repeal in 1996, after which it remains prohibited under broader Class A controls for synthetic amphetamines, with ongoing detections in ecstasy pills prompting public health alerts.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/31721
  2. https://go.drugbank.com/drugs/DB01472
  3. https://pubmed.ncbi.nlm.nih.gov/14616331/
  4. https://pubmed.ncbi.nlm.nih.gov/11599618/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4382046/
  6. https://pubmed.ncbi.nlm.nih.gov/29453997/
  7. https://pubmed.ncbi.nlm.nih.gov/12733852/
  8. https://pubmed.ncbi.nlm.nih.gov/12742705
  9. https://www.chemspider.com/Chemical-Structure.29417.html
  10. https://www.lookchem.com/ProductWholeProperty_LCPL521460.htm
  11. https://www.swgdrug.org/Monographs/p-METHOXYAMPHETAMINE.pdf
  12. https://cdn.caymanchem.com/cdn/msds/12041m.pdf
  13. https://www.sciencedirect.com/science/article/abs/pii/S0379073802001214
  14. https://core.ac.uk/download/357383567.pdf
  15. https://www.researchgate.net/publication/12270982_Synthesis_of_4-methyl-5-arylpyrimidines_and_4-arylpyrimidines_Route_specific_markers_for_the_Leuckardt_preparation_of_amphetamine_4-methoxyamphetamine_and_4-methylthioamphetamine
  16. https://pubmed.ncbi.nlm.nih.gov/12742705/
  17. https://www.researchgate.net/publication/10763215_Anise_oil_as_para-methoxyamphetamine_PMA_precursor
  18. https://chemistry.mdma.ch/hiveboard/rhodium/pdf/forensic/anethole.pma.precursor.pdf
  19. https://pubmed.ncbi.nlm.nih.gov/313827/
  20. https://www.sciencedirect.com/science/article/pii/S0278584600001135
  21. https://www.sciencedirect.com/science/article/abs/pii/S0014299906007734
  22. https://pubmed.ncbi.nlm.nih.gov/582863/
  23. https://pubmed.ncbi.nlm.nih.gov/19428944/
  24. https://www.tandfonline.com/doi/abs/10.3109/00498257409052058
  25. https://dmd.aspetjournals.org/article/S0090-9556%2824%2905431-X/fulltext
  26. https://adf.org.au/drug-facts/pma-and-pmma/
  27. https://www.researchgate.net/publication/11951841_Poisoning_with_the_recreational_drug_paramethoxyamphetamine_death
  28. https://.org/experiences/exp.php?ID=92266
  29. https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Para-Methoxyamphetamine/
  30. https://pubmed.ncbi.nlm.nih.gov/11041537/
  31. https://erowid.org/experiences/exp.php?ID=92266
  32. https://www.erowid.org/experiences/subs/exp_PMA.shtml
  33. https://psychonautwiki.org/wiki/PMA
  34. https://pubmed.ncbi.nlm.nih.gov/1174022/
  35. https://pubmed.ncbi.nlm.nih.gov/11599617/
  36. https://www.sciencedirect.com/science/article/abs/pii/S0091305710003874
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC5008716/
  38. https://www.sciencedirect.com/science/article/abs/pii/S0379073816302821
  39. https://academic.oup.com/jat/article-pdf/22/2/169/2341565/22-2-169.pdf
  40. https://pubmed.ncbi.nlm.nih.gov/12820749/
  41. https://pubmed.ncbi.nlm.nih.gov/12908947/
  42. https://ecddrepository.org/sites/default/files/2023-04/5.6_pmma_crev.pdf
  43. https://pubmed.ncbi.nlm.nih.gov/12126197/
  44. https://www.nature.com/articles/226644a0
  45. https://www.nature.com/articles/229133a0
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC1947522/
  47. https://www.release.org.uk/drugs/pmma-pma/history
  48. https://academic.oup.com/jat/article-pdf/25/7/649/2172002/25-7-649.pdf
  49. https://pubmed.ncbi.nlm.nih.gov/9760094/
  50. https://www.abc.net.au/news/2013-05-02/authorities-worry-as-deadly-drug-makes-comeback/4665776
  51. https://www.mja.com.au/journal/2002/177/8/death-and-paramethoxyamphetamine-evolving-problem
  52. https://pubmed.ncbi.nlm.nih.gov/22148985/
  53. https://www.irishtimes.com/news/health/warning-about-pma-pmma-drug-after-six-deaths-in-ireland-1.1832118
  54. https://pubmed.ncbi.nlm.nih.gov/9547415/
  55. https://academic.oup.com/jat/article-pdf/25/7/645/2171989/25-7-645.pdf
  56. https://www.theguardian.com/science/sifting-the-evidence/2013/oct/07/pma-ecstasy-club-drug-deaths-mdma
  57. https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/NDA073%2520Fact%2520Sheet%2520PMA.pdf
  58. http://www.drugs.ie/pma
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC7405356/
  60. https://www.tandfonline.com/doi/abs/10.3109/10826084.2013.852584
  61. https://www.researchgate.net/publication/261999987_PMA_Sounds_Fun_Negotiating_Drug_Discourses_Online
  62. https://www.publichealth.hscni.net/news/pha-advice-preventing-stimulant-related-deaths
  63. https://core.ac.uk/download/pdf/195665827.pdf
  64. https://researchnow.flinders.edu.au/en/publications/a-review-of-impurity-profiling-and-synthetic-route-of-manufacture
  65. https://www.semanticscholar.org/paper/Anise-oil-as-para-methoxyamphetamine-%28PMA%29-Waumans-Bruneel/9bd35891225143ada10f465e57092f1e77af2e56
  66. https://www.researchgate.net/publication/11750001_Fatalities_Caused_by_the_MDMA-Related_Drug_Paramethoxyamphetamine_PMA
  67. https://dataunodc.un.org/es/node/1485
  68. https://www.law.cornell.edu/cfr/text/21/1308.11
  69. https://www.deadiversion.usdoj.gov/schedules/orangebook/a_sched_alpha.pdf
  70. https://www.law.cornell.edu/uscode/text/21/812
  71. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
  72. https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/1971_Schedules/ST-CND-1-Add2_E.pdf
  73. https://www.unodc.org/documents/commissions/CND/Drug_Resolutions/1980-1989/1986/CND_Decision-1986-03_S-IX.pdf
  74. https://digitallibrary.un.org/record/122237
  75. https://www.incb.org/documents/Psychotropics/conventions/convention_1971_en.pdf
  76. https://www.unodc.org/pdf/convention_1971_en.pdf
  77. https://www.federalregister.gov/documents/2020/05/15/2020-09599/schedules-of-controlled-substances-placement-of-para-methoxymethamphetamine-pmma-in-schedule-i
  78. http://classic.austlii.edu.au/au/legis/qld/consol_reg/dmr1987256/sch3.html
  79. https://assets.publishing.service.gov.uk/media/5a82bea7ed915d74e62376a5/UK-drug-situation-2016-report.pdf
  80. https://legislation.govt.nz/act/public/1975/0116/latest/DLM436576.html
Add your contribution
Related Hubs
User Avatar
No comments yet.